Abstract
BackgroundIL-2 was approved for the treatment of metastatic renal cell carcinoma and melanoma as an immune-oncology agent. However, its biased binding to IL-2 receptor (IL-2R) alpha requires a high-dose administration,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
